The oral adsorbent AST-120 has been widely used in Japan to delay the initiation of dialysis therapy in patients with chronic renal failure. This study evaluated the longterm effects of AST-120 in patients with chronic renal failure who had not previously undergone dialysis. One hundred out-patients were prospectively enrolled and prescribed 6 g/day oral AST-120 for ≥ 1 year. The clinical effectiveness of AST-120 was evaluated by comparing changes in the slope of the reciprocal serum creatinine-time plot (1/sCr slope) before and after AST-120 administration. The 1/sCr slope improved significantly after ≥ 1 year of AST-120 treatment and greatest improvement was observed in patients with the longest AST-120 administration period (> 30 months). The results suggest that longterm treatment with AST-120 may be beneficial for chronic renal failure patients in the pre-dialysis stage.
Introduction
According to the Annual Report of the Japanese Society for Dialysis Therapy, the number of patients on maintenance dialysis therapy for end-stage renal disease was 257 765 at 31 December 2005. 1 The number of new patients in Japan who start dialysis exceeds 30 000 annually and this figure is increasing every year. From 1998, diabetic nephropathy (DMN) replaced chronic glomerulonephritis (CGN) as the primary cause of chronic renal failure, 1 and the incidence of nephrosclerosis (NS) has also risen. 1 Among patients who have been initiated on maintenance dialysis, 78% have at least one of these three major diseases. 1 This increase in the number of chronic renal failure patients has led to social and economic problems, not only in Japan but also in many other countries. 2 It is, therefore, necessary to establish more effective therapy to stop or delay the progression of chronic renal failure. Many useful treatment strategies, such as a low-protein diet or antihypertensive drugs, are available, however, it is widely accepted that integrated treatment strategies need to be established to improve the management of chronic renal failure. 2 K Maeda, C Hamada, T Hayashi, et al.
Long-term effects of oral adsorbent, AST-120
The so-called 'uraemic toxins', such as indoxyl sulphate, are biologically active substances involved in the progression of renal failure and many previous reports have shown that they may play an important role in the progressive loss of intact nephrons. 3, 4 The oral adsorbent, AST-120, has been developed to inhibit progression of renal failure by lowering uraemic toxin levels 5 and is used in many Japanese patients with chronic renal failure. Although the efficacy of AST-120 has been reported in both basic and clinical studies, 6,7 data on its long-term use are inadequate. The objective of this study was, therefore, to evaluate the long-term effects of AST-120 in patients with chronic renal failure who had not previously undergone dialysis.
Patients and methods

PATIENTS AND TREATMENT
Out-patients with chronic renal failure who had not previously undergone (and were not currently on) dialysis, who attended Juntendo University Hospital or Juntendo Shizuoka Hospital from 1999 to 2004, were prospectively enrolled into the study. All patients were followed and had data collected for ≥ 6 months (months -6 to 0). At month 0 they were started on 6 g/day AST-120 (Kremezin ® ; Kureha Corporation, Tokyo, Japan) orally and continued for ≥ 1 year. Clinical data (blood pressure and creatinine) were recorded monthly.
The investigators explained the purpose of the study to the patients at the time of study entry and written informed consent was obtained from all patients. The study was approved by the institutional review board of Juntendo University and was conducted in accordance with the Declaration of Helsinki.
Data from patients who started dialysis at the Juntendo University between 2000 and 2003, who were not prescribed AST-120 prior to undergoing dialysis were collected as a non-treatment control comparison.
EVALUATION OF AST-120 TREATMENT
Serum creatinine was measured by the standard enzymatic method and the primary clinical efficacy of AST-120 was evaluated by comparing the change in the reciprocal of the serum creatinine (sCr)time plot slope (1/sCr) before and after AST-120 administration for all patients. For the purpose of a reference, the 1/sCr slope of non-treatment control data was evaluated.
The effect of different treatment periods, and the effects of the primary cause of chronic renal failure, age and sCr levels at the start of AST-120 treatment were also analysed using the 1/sCr slope. For the effect of AST-120 treatment period, patients were classified into three groups: < 20 months; 20 -30 months; and > 30 months of AST-120 treatment. For classification by age, patients were also divided into three groups: < 60 years old; 60 -70 years old; and > 70 years old. For the effect of baseline sCr levels, patients were divided into two groups: those with baseline sCr ≤ 2 mg/day, or > 2 mg/dl.
STATISTICAL ANALYSIS
Statistical comparison of the 1/sCr slope before and after AST-120 treatment was performed using the paired Student's t-test. P-values < 0.05 were considered to be statistically significant.
Results
PATIENTS
Patient characteristics for the AST-120 treatment groups are shown in Table 1 . One hundred out-patients (64 men and 36 women) were enrolled to receive AST-120: 31 patients had DMN, 31 had NS and 21 patients K Maeda, C Hamada, T Hayashi, et al. Long-term effects of oral adsorbent, AST-120 had CGN, therefore the overall prevalence in the treatment group of these three major diseases was 83%. Patients' ages ranged from 29 to 84 years (mean ± SD 67.8 ± 17.8 years). The mean ± SD AST-120 treatment period was 29.3 ± 12.6 months (range 12.0 -102.0) and the mean ± SD sCr level at the start of AST-120 treatment was 2.9 ± 1.0 mg/dl. Records from 67 subjects (36 men and 31 women) comprised the control, which included 18 patients with DMN; eight with NS; and 21 with CGN, giving an overall prevalence of these three major diseases of 70%. Although the difference in between-group prevalence was significant (P = 0.0221; χ 2 -test), the AST-120 treatment group having more DMN and NS patients and they would be expected to be at higher risk of end-stage renal disease, the primary measure in this study was a change in 1/sCr slope for patients given AST-120 so it was decided that differences in the original disease could be ignored. Age was not recorded in the control group.
The numbers of patients categorized according to length of AST-120 treatment were: < 20 months, n = 32; 20 -30 months, n = 32; and > 30 months, n = 36. Patient numbers according to age group were: < 60 years old, n = 33, 60 -70 years old, n = 34; and > 70 years old, n = 33. Categorization according to baseline sCr level was ≤ 2 mg/dl, n = 27; and > 2 mg/dl, n = 73. Mean ± SD sCr concentrations during the study period in the AST-120 treatment group increased from 2.9 ± 1.0 mg/dl to 4.9 ± 2.9 mg/dl and 14 patients were introduced to haemodialysis.
CHANGE IN 1/SCR SLOPE OVER TIME
Treatment with AST-120 resulted in a statistically significant improvement in the mean 1/sCr slope from -0.012 ± 0.013 before AST-120 treatment to -0.006 ± 0.006 after treatment (P < 0.001; Fig. 1 ). In all patients, AST-120 administration was estimated to delay the initiation of dialysis by 21.2 months, assuming that initiation of dialysis was based on a sCr level of 8 mg/dl ( Fig. 2A) . The mean ± SD slope of 1/sCr in the control group was -0.016 ± 0.012.
CHANGE IN 1/SCR SLOPE BY TREATMENT PERIOD
Patients were classified into three groups according to the treatment period of AST-120. The mean ± SD treatment period for the patients in the < 20 months treatment group was 17.0 ± 2.7 months (n = 32), for those in the 20 -30 months treatment group it was 24.9 ± 3.3 months (n = 32) and for those in the > 30 months treatment group it was 44.3 ± 12.4 months (n = 36). There was no significant difference in slope, age distribution and sCr level at the start of treatment between the three treatment period groups (data not shown). For each treatment period, Fig. 2B shows change in 1/sCr slope before and after treatment, and the estimated time to initiation of dialysis. Administration of AST-120 significantly improved the 1/sCr slope after treatment compared with before treatment (P < 0.05 in the < 20 months and 20 -30 months treatment groups; P < 0.001 in the > 30 months treatment group) resulting in a prolonged estimated time until initiation of dialysis in all three groups; a greater effect was observed among patients who were given longer AST-120 treatment (Fig. 2B ).
CHANGE IN 1/SCR SLOPE BY PRIMARY CAUSE OF RENAL INSUFFICIENCY
The 1/sCr slope before and after the treatment was also compared for the three major primary causes of renal insufficiency, CGN, DMN and NS (Fig. 3) . Although the slope before treatment was different for each K Maeda, C Hamada, T Hayashi, et al. Long-term effects of oral adsorbent, AST-120 primary cause, AST-120 treatment significantly improved the 1/sCr slope and estimated progression of renal failure in all three groups (CGN, P < 0.05; DMN, P < 0.01; NS, P < 0.05). Comparison of the 1/sCr slope for the treated group versus non-treatment controls showed that the gradient of the slope for each primary cause was similar to control patients before treatment, but it was improved compared with controls for each primary cause after AST-120 treatment.
CHANGE IN 1/SCR SLOPE BY AGE AND BASELINE SCR LEVELS
For all age groups, there was a significant improvement in the 1/sCr slope after treatment with AST-120 compared with before treatment initiation (P < 0.05 -P < 0.001; Fig. 4 ). Patients > 70 years old showed a greater improvement in the 1/sCr slope compared with younger age groups. Comparison by baseline sCr levels showed no difference in 1/sCr slope for patients who had a baseline sCr of ≤ 2 mg/dl or > 2 mg/dl before receiving ART-120 treatment, however both groups demonstrated a significant improvement in 1/sCr slope after AST-120 treatment (P < 0.05 -P < 0.001; Fig. 5 ).
Discussion
The present study demonstrated that administration of the oral adsorbent, AST-120, significantly slowed disease progression in patients with chronic renal failure who had not previously undergone dialysis, based on differences in the 1/sCr slope before and after treatment. Treatment with AST-120 was estimated to delay the need for dialysis by 21.2 months.
Longer treatment with AST-120 was associated with an improved 1/sCr slope and a longer estimated time until initiation of dialysis, suggesting that the clinical effect of AST-120 treatment may be proportional to the administration period. Meanwhile, Takahashi et al. 8 has reported, in a postmarketing survey of 48 undialysed patients with a median sCr level of 4.3 mg/dl, that long-term (2-year) use of AST-120 suppressed progressive loss of renal function. Thus, AST-120 treatment should continue for as long as possible even if the sCr concentration rises and should not be discontinued after only a short period in patients with chronic renal failure. In terms of when to start Shoji et al. 7 showed that, in patients with chronic kidney disease whose glomerular filtration rate level was 20 -70 ml/min, the early co-administration of AST-120 with conventional treatments retarded glomerular filtration rate decline. It may also be that starting AST-120 treatment in the early stage of chronic renal failure could further improve outcomes, although this needs to be fully investigated. Significant improvements were observed in the 1/sCr slope for patients with CGN, DMN or NS, suggesting that a decrease in uraemic toxin levels can improve chronic renal insufficiency independent of the primary cause. In addition, improvement in the 1/sCr slope was independent of sCr levels before AST-120 administration.
The decrease in the 1/sCr slope was greater in patients > 70 years of age than in younger patients. The reason is unknown and needs to be investigated in further studies. It may be, however, that older patients have better compliance than younger patients or, since elderly patients tend to eat less, it might be easier for them to maintain a low-protein diet and this might result in an improved effect with AST-120. The clinical effect of AST-120 in delaying the progression of chronic renal failure involves adsorption of uraemic toxins in the digestive tract. 9,10 Since protein-bound uraemic toxins, such as indoxyl sulphate, cannot be Goto et al. 11 on patients with diabetic nephropathy and sCr levels ≥ 1.3 mg/dl (mean 3.1 mg/dl), despite only a small number of cases being examined, inhibition of renal failure progression together with a decrease in serum indoxyl sulphate levels were observed following administration of AST-120. It may, therefore, be that the delayed progression of chronic renal failure in patients given AST-120 seen in the present study was due to inhibited accumulation of uraemic toxins, although further prospective study is needed to elucidate the association between changes in uraemic toxin levels and the effect of AST-120 before any conclusion can be made.
The primary goal of chronic renal failure treatment is avoidance or delay of dialysis therapy. To achieve a good outcome in the treatment of chronic renal failure, an integrated treatment programme is necessary. A strategy to achieve this goal would be to combine treatment of the primary disease with treatment to suppress progression of renal dysfunction (such as life-style counselling, low-protein diet and medication), and proper preparation and education of patients for dialysis therapy. Based on the results reported here, the addition of AST-120 to the above strategy is likely to enhance the success rate of treatment for chronic renal failure. Although the clinical effects of AST-120 are well known, 7 -11 compliance is a problem due to the volume of AST-120 granules that need to be taken. Proper education on the benefits of AST-120 treatment and compliance is, therefore, required.
In conclusion, the long-term treatment of chronic renal failure with AST-120 appears to be beneficial in slowing the progression of renal failure and delaying the initiation of dialysis. This conclusion, however, needs to be treated with some caution due to the fact that the present study was a retrospective analysis. In addition, the effects of AST-120 may have been overestimated since it was not possible to eliminate the speculation that those patients who did not require dialysis and who were in a stable condition would tend to continue dosing with AST-120 for a long period. In order to examine the association between the long-term administration and usefulness of AST-120, prospective research in patients with early stage of chronic kidney disease is needed.
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